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Background
No clear information on the optimal dosage of Canaki-
numab in CAPS is available.
Aim
To analyse the modification of dosage schedule of Cana-
kinumab in CAPS in 12 months of routinely clinical
practice.
Methods
12 patients (9 children and 3 adults) with Muckle-Wells
syndrome (3), MWS/CINCA overlap (3) and CINCA (6)
were analyzed. Patients were previously enrolled in the
CACZ885D2306 trial and studied for the following 12
months.
Results
At baseline, 7 patients were treated with the initial
d o s a g eo f2m g / k g( o r1 5 0m g ,i f>4 0K g )e v e r y
8 weeks. In 5 patients (2 MWS/CINCA overlap, 5
CINCA) the dosage was 4 mg/kg (or 300 mg) every 8
weeks.
During the following 12 months modification of
dosage of frequency was performed in 7/12 patients.
The 5 patients at higher dosage during the
CACZ885D2306 study needed to increase the frequency
of administration with a mean frequency of 6 weeks
(range 4-8). The mean reason was the presence of mild
clinical manifestation and/or persistent elevation of
acute phase reactants. In one of these patients the ther-
apy was subsequently discontinued due to persistent dis-
ease activity. An increased frequency (6 and 7 weeks)
was also performed in 1 MWS and 1 CINCA patient,
respectively.
In 5 patients the treatment was not modified being
effective in the control of the disease.
Conclusions
This study confirms the efficacy of Canakinumab in
CAPS. However, pediatric patients and those with a
more severe phenotype require higher and more fre-
quent dosage than previously described.
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